The present study reports the isolation of a cDNA clone that encodes a second member of the corticotropin-releasing factor (CRF) receptor family, designated as the CRF2 receptor. The cDNA was identified using oligonucleotides of degenerate sequence in a PCR paradigm. A PCR fragment obtained from rat brain was utilized to isolate a full-length cDNA from a rat hypothalamus cDNA library that encoded a 411-amino acid protein with "70% identity to the known CRF1 receptor over the entire coding region. When expressed in mouse Ltk-cells, this receptor stimulates cAMP production in response to CRF and known CRF-like agonists. CRF and the nonmammalian CRF-related peptides sauvagine and urotensin I stimulate adenylate cyclase activity in a dose-dependent manner with a rank order of potency different from that of the CRF1 receptor: sauvagine > urotensinrat/human CRF > ovine CRF. Tissue distribution analysis of the mRNAs by reverse transcriptase-PCR shows CRF2 receptor mRNA is present in rat brain and detectable in lung and heart. In situ hybridization studies indicate specific expression within the brain in the ventromedial nuclei of the hypothalamus, the lateral septum, the amygdala, and entorhinal cortex, but there is unremarkable expression in the pituitary. An additional splice variant of the CRF2 receptor with a different N-terminal domain has been identified by PCR, encoding a putative protein of 431 amino acids. Thus, the data demonstrate the presence of another functional CRF receptor, with significant differences in the pharmacological profile and tissue distribution from the CRF1 receptor, which would predict important functional differences between the two receptors.
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Corticotropin-releasing factor (CRF), a 41-amino acid peptide, regulates the secretion of adrenocorticotropin and other proopiomelanocortin products from the anterior pituitary. CRF also coordinates the endocrine, behavioral, and autonomic responses to stress. Within the past few years, substantial evidence has accumulated from both laboratory and clinical studies implicating CRF as a physiological mediator of stress responses and stress-induced disorders (1) (2) (3) (4) (5) (6) . Immunocytochemical studies have shown that CRF is found within the paraventricular nucleus of the hypothalamus as well as limbic areas such as the central and medial nuclei of the amygdala, the bed nucleus of the stria terminalis, substantia inominata, septum, preoptic area, the lateral hypothalamus, and brain stem nuclei involved in stress responses and regulation of autonomic function, such as the locus coeruleus, the parabrachial nucleus, and the dorsal vagal complex (see ref. 7) . CRF, when administered intracerebroventricularly, results in behavioral, physiological, and autonomic responses that are similar to those observed when animals are exposed to a stressful environment (4) (5) (6) .
CRF mediates its action through high-affinity membrane receptors that have been extensively characterized by radioligand binding studies in brain and pituitary (for review, see ref. 8) . A receptor for CRF has recently been cloned and functionally expressed by three groups (9) (10) (11) (12) . This receptor, designated as CRF1, is a member of a distinct family of seven transmembrane domain receptors, which includes receptors for calcitonin, vasoactive intestinal peptide (VIP), parathyroid hormone, and others (13) . The receptor is potently activated by CRF and sauvagine, the related frog skin peptide, to stimulate adenylate cyclase. Its mRNA is predominantly expressed in cerebellum, pituitary, cerebral cortex, and olfactory bulb, which is consistent with the primary sites of action of CRF.
While there is a general correspondence of the distribution of 125I-labeled CRF binding sites and CRF1 receptor mRNA in brain with the functional actions of CRF, there are several brain areas with some apparent discrepancies. For example, there is a generally low level of expression and uniform distribution of 125I-labeled CRF binding sites and CRF1 receptor mRNA in the hypothalamus, whereas CRF has robust in vitro and in vivo effects in hypothalamus on neuroendocrine, autonomic, and behavioral parameters (4, 5, 8, 14, 15) . Similarly, CRF has potent electrophysiological and behavioral effects in the locus coeruleus while the distribution of 1251-labeled CRF binding sites and CRF, receptor mRNA is not notable in this brainstem nucleus (4, 5, 8, 14) . This and the observation that CRF exerts multiple peripheral functions led us to hypothesize the existence of other CRF receptor subtypes that could account for such effects. Accordingly, we designed a degenerate PCR experiment based on the known human, rat, and mouse sequences of the CRF1 receptor. Here we present data showing the existence of a second CRF receptor (designated CRF2 receptor) § isolated from rat brain and describe experiments addressing its functional characterization and tissue localization.
MATERIALS AND METHODS PCR Cloning and Sequence Analysis. Poly(A)+ RNA was isolated from whole rat brain (excluding cerebellum) and lung by using PolyATract mRNA isolation kits (Promega). Firststrand cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Promega), which was subsequently dG-tailed by terminal deoxynucleotidyltransferase (Promega). This procedure adds a homopolymer tail of -18 deoxyguanine nucleotides at the 3'-OH of the first-strand cDNA. 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. domain 7 of the CRF1 receptor (Met-Phe-Gly-Glu-Gly-CysTyr and Tyr-Cys-Phe-Leu-Asn-Ser-Glu, respectively). Nucleotide sequences of primers (5' to 3' with N = A,T,G, or C; Y = T or C; R = A or G) were (17) with modifications to adapt the assay to whole cell preparations. The standard assay mixture contained the following components in a final volume of 0.5 ml: 2 mM L-glutamine, 20 mM Hepes, and 1 mM isobutylmethylxanthine in DMEM. In stimulation studies, whole cells containing the transiently transfected CRF2 receptor or stably transfected CRF2 receptor were incubated for 1 h at 37°C with various concentrations of CRF-related and unrelated peptides. After the incubation, the medium was aspirated, and the cells were rinsed once gently with fresh medium. Next, 300 ,ul of 95% ethanol/20 mM HCl (EtOH/HCl) was added to each well and incubated at -20°C for 16-18 h. The solutions were removed to 1.5-ml Eppendorf tubes, and the wells were washed with an additional 200 ,lI of EtOH/HCl, which was pooled with the first fraction. The samples were lyophilized and resuspended with 500 ,ul of 0.05 M sodium acetate (pH 6.2). The measurement of cAMP in the samples was performed using a radioimmunoassay kit from Biomedical Technologies (Stoughton, MA).
In Situ Hybridization. Rats were sacrificed by decapitation, and brains and pituitaries were removed and frozen in liquid isopentane (-42°C (18) (19) (20) . However, this procedure typically requires the design of at least three degenerate oligonucleotides. The first two oligonucleotides are used to create an enriched "template" for the second round of PCR, which then requires an additional oligonucleotide corresponding to target DNA created in the first round. Each new oligonucleotide requires the presence of a corresponding sequence in the target gene and, therefore, increases the risk of missing related genes. To reduce this risk, an anchor-PCR was combined with nested degenerate oligonucleotides. This procedure reduces the number of necessary degenerate oligonucleotides to two, thus increasing the probability of identifying sequences related to the initial template design (in this case the CRF receptor).
Initially, a single degenerate antisense oligonucleotide (corresponding to a portion of transmembrane domain 7) in combination with a poly(dC) oligonucleotide was used to selectively amplify from first-strand rat brain dG-tailed cDNA. Next, oligonucleotide primers of degenerate sequence corresponding to an amino acid sequence in the putative transmembrane domain 3 from the known CRF receptor was used in combination with the original degenerate oligonucleotide to amplify DNA fragments from the first reaction. Amplification products were size-selected, subcloned, and sequenced. In one experiment, 24 products were subcloned, 8 of which were picked (based on size) for sequencing. Seven of these matched the known sequence for the cloned rat CRF receptor (9, 12 (Fig. 1) . The protein exhibits seven putative hydrophobic regions corresponding to
TCCTGATGACAAAACTGCGAGCCTCCACCACATCCGAGACCATCCAGTACAGGAAGGCAG 925
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TGAAGGCCACCCTGGTCCTCCTCCCCCTGTTGGGCATCACCTACATGCTCTTCTTTGTCA 985 (Fig. 2) . It shows '30% homology with other members of this neuropeptide receptor superfamily.
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In the anchor-PCR approach, an oligonucleotide specific to CRF2 was used in a paradigm similar to that described above for degenerate oligonucleotides except dG-tailed lung cDNA was included as template, in addition to dG-tailed brain cDNA. The sequence of some of the fragments isolated from brain were identical to the hypothalamus cDNA clone. However, others from both brain and lung cDNAs were identical only from amino acid 35 onward. The 5' end of these clones had the first 34 amino acids replaced with an ORF of 54 amino acids, including a translational start codon. We have tentatively named the two apparent splice forms of the receptor CRF2a, and CRF20 for the hypothalamus and brain/lung forms, respectively. The CRF2, form encodes a putative protein of 431 amino acids and the 5' sequence is indicated in Fig. 1 . Chen et aL (10) found, in their human cDNA for CRF receptor, two apparent splice forms of the same receptor, which they named CRF-R1 and CRF-R2. Their CRF-R1 form appears to be the predominant form and no species homolog or tissue specificity has been identified for the CRF-R2 form. We propose that The CRF1 receptor has been cloned (9-12) and shown to be linked to the stimulation of adenylate cyclase. Since the CRF2 receptor shows striking similarity to the CRF1 receptor, particularly in the third intracellular domain, it was presumed to share this functional linkage. To confirm that the CRF2 receptor couples to the stimulation of adenylate cyclase, the receptor cDNA was subcloned into an expression vector (pCDM7-Amp) and transiently transfected into mouse Ltkcells. Cells transfected with CRF2 responded in a dosedependent manner to rat/human CRF (r/hCRF), ovine CRF (oCRF), and the CRF-related peptides sauvagine and urotensin I (Fig. 3B ) with half-maximal efficacy (EC5o) values of '20 nM, 80 nM, 0.5 nM, and 2 nM, respectively. In Ltk-cells stably overexpressing the CRF, receptor, r/hCRF, oCRF, sauvagine, and urotensin were nearly equipotent at stimulating cAMP accumulation (Fig. 3A) with EC50 values of -4 nM, 10 nM, 3 nM, and 4 nM, respectively. Furthermore, the unrelated peptides VIP, vasopressin, and growth hormone-releasing hormone did not stimulate any cAMP production in these cells. In addition, the biologically weak deamidated form of CRF was 100-to 1000-fold less potent than the native form, confirming the structural requirements for specificity at both receptors. Transient transfection of the CRF1 receptor in Ltk-cells yielded essentially identical results to the stable transfections. The maximal stimulation of cAMP accumulation induced through the CRF1 receptor was greater than the CRF2 receptor (Fig. 3) An intriguing aspect of the CRF2 receptor is the finding that sauvagine and urotensin I are more potent activators than CRF itself. Sauvagine and urotensin I are CRF-like peptides that have been isolated from frog and fish, respectively (22, 23) . Sauvagine has been shown to be equipotent with CRF at the CRF, receptor (9) , and urotensin I has been shown to sauvagine (24) . In addition, sauvagine and urotensin I have been reported to have behavioral and autonomic effects that are more potent than CRF itself (25) , suggesting that these actions may be mediated in part by CRF2 receptors. Since CRF itself is also found in fish (22) However, by reverse transcriptase-PCR, we were able to detect receptor message in the brain, lung, kidney, and heart. Since PCR is extremely sensitive and difficult to quantify, in situ hybridization histochemistry was used to localize CRF2 receptor mRNA expression. An antisense RNA probe complementary to the CRF2 receptor was synthesized (-66% homology to CRF1 receptor). The specificity of the hybridization signal was established by confirming a lack of hybridization in sections treated with a sense-strand RNA probe and sections pretreated with RNase A prior to hybridization with antisense RNA probe. By using the antisense CRF2 RNA probe, significant levels of hybridization were evident in many brain regions. Prominent expression was evident in lateral septum, the ventromedial nucleus of the hypothalamus, several amygdaloid nuclei, and the entorhinal cortex (Fig. 4) . CRF2 receptor mRNA expression was undetectable in neocortex and cerebellar cortex, in contrast to the high levels of CRF1 receptor expression in these regions (14) . Similarly, CRF2 receptor expression was unremarkable in pituitary lobes where CRF1 receptor expression is readily detectable (14) .
This heterogeneous distribution of CRF receptor subtypes is likely to reflect distinct functional roles for CRF2 receptors vs. CRF1 receptors within the brain. Of the areas with high expression levels of CRF2 mRNA, evidence from lesion and electrode stimulation studies suggests that the ventromedial hypothalamic nucleus is critical for food intake regulation (26) , whereas the lateral septum, amygdala, and entorhinal cortex are intimately involved in limbic circuitry associated with determining the affective state.
There are several lines of preclinical and clinical evidence that support a role for brain CRF in neuropsychiatric, neurodegenerative, metabolic, and feeding disorders (see refs. 1 and 27) . Briefly, the data suggest that CRF may be hypersecreted in brain in major depression, anxiety-related disorders, and anorexia nervosa. In contrast, deficits in brain CRF may contribute to dementia associated with neurodegenerative disorders such as Alzheimer disease. Furthermore, hypofunction of hypothalamic CRF has been implicated in the development of obesity syndromes. The identification of CRF2 receptors will now allow a more precise definition of the CRF functional pathways and provide the basis for the development of selective research tools and/or therapeutics specifically targeted toward these systems.
SUMMARY
The data presented in this study describe a gene that encodes a member of the CRF receptor family (CRF2 receptor). Analysis of the CRF2 receptor has revealed several interesting aspects of CRF physiology. (i) The CRF2 receptor exhibits a distinct pharmacological profile from the CRF1 receptor. ( ii) The distribution of CRF2 receptor mRNA shows a unique highly localized distribution in the brain, with prominant expression in the limbic regions. This is in contrast to CRF1 receptor (14) or the CRF-binding protein (28) , which are both widely and somewhat codistributed throughout the brain, particularly in cerebral cortex and in pituitary. In accordance with these findings, it can be hypothesized that different aspects of CRF physiology may be altered by drugs displaying selectivity for CRF1 vs. CRF2 receptors. It is tempting to speculate that the two receptor subtypes will mediate different aspects of CRF function in the central nervous system, such as appetite control, stress response, anxiety, or depression. Thus, determining the specific role of the CRF2 receptor within the brain not only will contribute to our understanding of central CRF systems but also may lead to the development of CRF receptor subtype-specific drugs.
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